NeoGenomics, Inc. (NEO) Insider Robert J. Shovlin Sells 180,000 Shares of Stock
NeoGenomics, Inc. (NASDAQ:NEO) insider Robert J. Shovlin sold 180,000 shares of the firm’s stock in a transaction dated Friday, November 9th. The shares were sold at an average price of $17.05, for a total value of $3,069,000.00. Following the completion of the sale, the insider now owns 339,884 shares of the company’s stock, valued at $5,795,022.20. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.
NASDAQ:NEO opened at $16.50 on Wednesday. The company has a current ratio of 4.13, a quick ratio of 3.98 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $1.58 billion, a P/E ratio of 275.00 and a beta of -0.01. NeoGenomics, Inc. has a 12 month low of $7.08 and a 12 month high of $19.04.
NeoGenomics (NASDAQ:NEO) last posted its quarterly earnings results on Tuesday, October 30th. The medical research company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.03. The company had revenue of $69.10 million for the quarter, compared to analysts’ expectations of $66.13 million. NeoGenomics had a net margin of 1.70% and a return on equity of 2.63%. NeoGenomics’s revenue was up 16.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.01 EPS. As a group, sell-side analysts expect that NeoGenomics, Inc. will post 0.11 EPS for the current year.
Several analysts have recently commented on NEO shares. Leerink Swann assumed coverage on NeoGenomics in a research note on Tuesday, August 21st. They issued an “outperform” rating and a $18.00 target price for the company. Craig Hallum raised their price target on shares of NeoGenomics from $17.00 to $22.00 and gave the company a “buy” rating in a research report on Wednesday, October 31st. Zacks Investment Research raised shares of NeoGenomics from a “hold” rating to a “strong-buy” rating and set a $21.00 price target on the stock in a research report on Saturday, November 3rd. First Analysis set a $16.00 price target on shares of NeoGenomics and gave the company a “buy” rating in a research report on Tuesday, September 18th. Finally, BidaskClub cut shares of NeoGenomics from a “strong-buy” rating to a “buy” rating in a research report on Friday, August 10th. One research analyst has rated the stock with a hold rating, nine have issued a buy rating and three have assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $20.00.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2018/11/14/neogenomics-inc-neo-insider-robert-j-shovlin-sells-180000-shares-of-stock.html.
NeoGenomics Company Profile
NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States. It operates through Clinical Services and Pharma Services segments. The company laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, and other clinical laboratories.
Recommended Story: How Do Tariffs Affect Trade Balances?
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.